Table 2.
Baseline Characteristics by Treatmenta
| Variable | n | Characteristics by Vitamin D Dose |
||||
|---|---|---|---|---|---|---|
| Placebo (n = 66) | 400 IU (n = 64) | 1000 IU (n = 65) | 2000 IU (n = 64) | 4000 IU (n = 64) | ||
| Age, y | 323 | 11.5 (1.2) | 11.3 (1.2) | 11.1 (1.1) | 11.4 (1.4) | 11.5 (1.2) |
| Anthropometry | ||||||
| Weight, kg | 323 | 45.5 (11.3) | 46.6 (10.4) | 46.1 (11.1) | 52.0 (14.8) | 46.7 (12.2) |
| Height, cm | 323 | 151 (8.9) | 151 (8.1) | 149 (9.2) | 153 (10.4) | 150 (9.4) |
| BMI-for-age, % | 323 | 63.3 (29.5) | 67.6 (27.8) | 70.4 (28.4) | 71.5 (30.4) | 67.4 (30.1) |
| Body compositionb | ||||||
| Fat mass, kg | 320 | 13.7 (7.0) | 14.3 (7.1) | 14.6 (7.3) | 16.3 (8.2) | 14.9 (7.5) |
| % body fat | 320 | 29.8 (8.9) | 30.8 (9.4) | 31.5 (9.9) | 31.6 (9.7) | 31.9 (9.0) |
| Lean mass, kg | 320 | 30.0 (6.3) | 30.1 (5.6) | 29.2 (5.8) | 32.9 (9.1) | 29.7 (6.6) |
| Biochemical3 | ||||||
| 25(OH)D, nmol/L | 318 | 71.5 (18.6) | 71.4 (19.5) | 71.1 (19.7) | 65.8 (7.3) | 70.0 (17.5) |
| 1,25(OH)2D, pmol/L | 318 | 146 (45) | 143 (40) | 140 (39) | 149 (44) | 142 (46) |
| iPTH, pg/mL | 318 | 26.6 (10.8) | 27.6 (9.1) | 26.2 (10.7) | 30.2 (12.8) | 26.4 (9.9) |
| Serum Ca, mg/dL | 305 | 9.8 (0.3) | 9.9 (0.3) | 9.9 (0.3) | 9.9 (0.3) | 9.8 (0.3) |
| Urine Ca (Ca/Cr) | 305 | 0.07 (0.06) | 0.07 (0.13) | 0.08 (0.10) | 0.05 (0.05) | 0.05 (0.05) |
| Fractional Ca absorption | 310 | 0.46 (0.16) | 0.45 (0.15) | 0.44 (0.20) | 0.47 (0.17) | 0.46 (0.17) |
| Dietary intake (per day) | ||||||
| Energy, kcal | 307 | 1978 (513) | 1996 (577) | 1986 (523) | 2000 (642) | 2048 (536) |
| Vitamin D, IU | 307 | 151 (96) | 198 (140) | 143 (111) | 184 (160) | 175 (101) |
| Calcium, mg | 307 | 837 (321) | 1000 (467) | 822 (375) | 914 (411) | 945 (378) |
| Energy expenditure, METs/d | 304 | 60.9 (8.2) | 63.8 (12.0) | 61.0 (10.0) | 63.0 (9.2) | 62.4 (10.3) |
a
Values are presented as means (SD).
b
Body composition measures assessed using DXA.